Sjögren’s Syndrome News

Clinical trial results in Sjögren’s disease over the last decade have volleyed between encouraging successes and deflating failures, but with several new drugs advancing through the pipeline, hopes are high yet again.

WASHINGTON — A 15 mg/kg dose of the neonatal fragment crystallizable receptor blocker nipocalimab outperformed placebo in improving Sjögren’s disease activity at 24 weeks, according to data presented at ACR Convergence 2024.

“Ankylosing spondylitis”? “Sjögren’s syndrome”?

Treatment with IV nipocalimab was safe and led to significant reductions in disease expression at 24 weeks in adolescents with generalized myasthenia gravis, according to data presented at AANEM.

The FDA has granted breakthrough therapy designation to nipocalimab, a novel neonatal Fc receptor blocker, for the treatment of moderate to severe Sjögren’s disease, according to a press release from Johnson & Johnson.

Despite being one of the most prevalent autoimmune diseases in the United States, Sjögren’s disease remains shrouded behind significant misconceptions and knowledge gaps that can delay diagnosis and appropriate treatment.

Systemic treatment strategies lower the risk for new Sjögren’s disease activity when there are complications with marginal zone lymphoma, according to a study published in The Lancet Rheumatology.

SAN DIEGO — Determining which of several phenotypes a patient with Sjögren’s disease falls under can help inform their treatment strategy, according to data presented at the 2024 Congress of Clinical Rheumatology West.

New recommendations from the American College of Rheumatology and the American College of Chest Physicians strongly advise against glucocorticoids for interstitial lung disease in systemic sclerosis.